TV personality Jason Silva debuts an AI-powered psychedelic film, blurring the lines between altered states, creative tech, and cannabis culture. What does this mean for DMV residents?

New EEG findings highlighted by DoubleBlind suggest baseline brain rhythms can forecast how intense an ayahuasca experience may feel—useful context for DMV readers.

Marijuana Moment reports a Texas Senate candidate’s alcohol-linked cash haul while opposing cannabis reform—plus new research on teen use and clinical science DMVers should track.

State health officials pulled back proposed fee increases for Oregon’s supervised psilocybin program after broad backlash, but funding questions and possible tax changes remain.

Learn how survivor-built vetting frameworks use color-coded flags to help consumers identify ethical guides and avoid abuse.

Psychedelic Alpha reports that Resilient has resubmitted its MDMA-for-PTSD application two years after a prior rejection. Here’s what to watch, timelines, and DMV impacts.

Definium Therapeutics reports another positive Phase 3 readout for DT120 in generalised anxiety disorder, with randomized data from the Panorama study now toplined.

As 5‑MeO‑DMT draws buzz, scientists and conservationists warn against “toad milking.” Here’s what’s known, what’s not, and how DMV readers should approach it.

Bipartisan federal moves and a new Louisiana pilot are reshaping psychedelic therapy research. Here’s how it intersects with dc cannabis research, patient access, and safety.

A new Psychedelic Alpha podcast surveys D.C.’s psychedelic moment, the FDA’s evolving medical framework, and New Zealand’s MDMA prescribers—here’s why the DMV should care.

A small Johns Hopkins pilot gave two psilocybin doses to 20 adults with chronic Lyme symptoms. Participants reported improved sleep and quality of life, and a 40% symptom drop at six months.

A plain‑English guide to where psychedelic-assisted therapy is actually available now, how Oregon, Colorado and New Mexico differ, and what DC, Maryland and Virginia residents should know before making plans.

From West Virginia to Hawaii, lawmakers are prepping for FDA-approved psilocybin drugs—not legalizing mushrooms. Here’s what’s moving, who’s behind it, and how it could affect DMV residents.

A Johns Hopkins pilot shows oral THC can feel psychedelic in controlled settings, reshaping dosing guidance, trial design, and how DMV consumers approach high-THC edibles.

DoubleBlind Mag reports how Lebanon, the UAE, Jordan, and Egypt are shaping psychedelic-assisted care, from ketamine clinics to policy debates and faith-informed practice.

Journalist Erica Rex urges caution: psychedelic states can open trauma and power imbalances. Here’s what ethical care, safety, and patient-centered practices should look like in the DMV.

Psychedelics are surging into the mainstream, but key knowledge holders remain sidelined. Here’s what that means for DC, Maryland, and Virginia readers in 2026.

A new nonprofit, After The Story, will fund legal psychedelic-assisted care and integration for reporters and media workers carrying trauma from the job.

DoubleBlind Mag spotlights rising 'pill shaming' in psychedelic spaces. Here’s what it means for people on SSRIs, the early research, and how DMV readers can stay safe.

MAPS linked with New Jersey’s HoneyProjects to bring education into a dispensary setting—its first retail cannabis partnership in 40 years—and it could reshape how patients learn.